MX2024013454A - Metodos de preparacion de concentrado del agrupamiento de cohn a partir de plasma sanguineo mediante ultrafiltracion - Google Patents

Metodos de preparacion de concentrado del agrupamiento de cohn a partir de plasma sanguineo mediante ultrafiltracion

Info

Publication number
MX2024013454A
MX2024013454A MX2024013454A MX2024013454A MX2024013454A MX 2024013454 A MX2024013454 A MX 2024013454A MX 2024013454 A MX2024013454 A MX 2024013454A MX 2024013454 A MX2024013454 A MX 2024013454A MX 2024013454 A MX2024013454 A MX 2024013454A
Authority
MX
Mexico
Prior art keywords
cohn
ultrafiltration
preparing
methods
blood plasma
Prior art date
Application number
MX2024013454A
Other languages
English (en)
Spanish (es)
Inventor
Ivano Martelli
Oliver Mieselberger
Francesca Micheli
Alexander Zaydenberg
Jarrod Hanson
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2024013454A publication Critical patent/MX2024013454A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/02—Reverse osmosis; Hyperfiltration ; Nanofiltration
    • B01D61/027—Nanofiltration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/58—Multistep processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D65/00—Accessories or auxiliary operations, in general, for separation processes or apparatus using semi-permeable membranes
    • B01D65/02—Membrane cleaning or sterilisation ; Membrane regeneration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2315/00—Details relating to the membrane module operation
    • B01D2315/16—Diafiltration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2321/00—Details relating to membrane cleaning, regeneration, sterilization or to the prevention of fouling
    • B01D2321/16—Use of chemical agents
    • B01D2321/162—Use of acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Water Supply & Treatment (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
MX2024013454A 2022-05-02 2024-10-31 Metodos de preparacion de concentrado del agrupamiento de cohn a partir de plasma sanguineo mediante ultrafiltracion MX2024013454A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263337439P 2022-05-02 2022-05-02
US202363498470P 2023-04-26 2023-04-26
PCT/US2023/066457 WO2023215722A1 (en) 2022-05-02 2023-05-01 Methods of preparing cohn pool concentrate from blood plasma through ultrafiltration

Publications (1)

Publication Number Publication Date
MX2024013454A true MX2024013454A (es) 2024-12-06

Family

ID=86646677

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024013454A MX2024013454A (es) 2022-05-02 2024-10-31 Metodos de preparacion de concentrado del agrupamiento de cohn a partir de plasma sanguineo mediante ultrafiltracion

Country Status (9)

Country Link
US (1) US20250281530A1 (https=)
EP (1) EP4518875A1 (https=)
JP (1) JP2025514479A (https=)
KR (1) KR20250004876A (https=)
CN (1) CN119300842A (https=)
AU (1) AU2023264066A1 (https=)
MX (1) MX2024013454A (https=)
TW (1) TW202400621A (https=)
WO (1) WO2023215722A1 (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390074A (en) 1942-02-09 1945-12-04 Research Corp Protein product and process
DE2902158A1 (de) * 1979-01-20 1980-07-31 Biotest Serum Institut Gmbh Verfahren zur herstellung von fibrinogen, einem die gerinnungsfaktoren ii, vii, ix und x enthaltenden prothrombinkomplex, antithrombin iii und einer loesung von lagerstabilen serumproteinen
US8304524B2 (en) * 2009-07-23 2012-11-06 Baxter International Inc. Manufacture of factor H (FH) and FH-derivatives from plasma
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
SG187599A1 (en) * 2010-07-23 2013-03-28 Baxter Int Manufacture of inter -alpha - inhibitor proteins (iaip) from plasma
US9403899B2 (en) * 2011-08-26 2016-08-02 Baxalta Incorporated Method for reducing the thromboembolic potential of a plasma-derived immunoglobulin composition
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
CN116322920A (zh) * 2020-11-09 2023-06-23 武田药品工业株式会社 使用氧化硅吸附从血浆中纯化fviii

Also Published As

Publication number Publication date
KR20250004876A (ko) 2025-01-08
JP2025514479A (ja) 2025-05-02
TW202400621A (zh) 2024-01-01
EP4518875A1 (en) 2025-03-12
CN119300842A (zh) 2025-01-10
WO2023215722A1 (en) 2023-11-09
US20250281530A1 (en) 2025-09-11
AU2023264066A1 (en) 2024-10-31

Similar Documents

Publication Publication Date Title
CO2023001489A2 (es) Proceso de fraccionamiento de plasma usando plasma humano secado por atomización
CL2024002249A1 (es) Muteína de il-21; conjugado; método de producción; composición farmacéutica; y su uso.
JOP20220092A1 (ar) جسم مضاد لبيتا-النشواني لعلاج مرض الزهايمر
AR113011A1 (es) Vesículas extracelulares bacterianas
MX2021010149A (es) Composiciones y metodos para tratar la distrofia cristalina de bietti.
AR076607A1 (es) Composicion acuosa. metodo para producir una preparacion altamente concentrada de inmunoglobulina de uso subcutaneo
EA201491155A1 (ru) Новые мутантные про-нрф и их применение для получения бета-нрф
GT200500254A (es) Proceso para la concentracion de anticuerpos y productos terapeùticos relacionados.
DE502004008588D1 (de) Agrochemische formulierungen
AR107020A2 (es) Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9)
CL2024002972A1 (es) Uso de un antagonista del vegf para tratar trastornos oculares angiogénicos.
RU2019126232A (ru) Пептиды и способы для лечения диабета
UY40209A (es) Proceso para preparar (15¿,16¿,17¿)-estra-1,3,5(10)-trieno-3,15,16,17-tetrol monohidrato (estetrol monohidrato)
MX2022002418A (es) Composiciones y metodos de tratamiento de enfermedades vasculares.
WO2020142740A8 (en) Treatment of sjogren's disease with nuclease fusion proteins
MX2022003585A (es) Metodos para tratar hiperfenilalaninemia.
MX2024013454A (es) Metodos de preparacion de concentrado del agrupamiento de cohn a partir de plasma sanguineo mediante ultrafiltracion
EA201591108A1 (ru) Слитый гормон роста человека и альбумин, составы и их применения
MX2024004003A (es) Proceso para preparar monohidrato de (15alfa,16alfa,17beta)-estra- 1,3,5(10)-trien-3,15,16,17-tetrol (estetrol).
CO2026000249A2 (es) Proteínas de fusión de citocinas únicas y múltiples y usos de estas
PH12022550254A1 (en) MICROMOLECULE PI4KIIIa INHIBITOR COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF
WO2023081194A3 (en) Methods for treating alzheimer's disease
MX2020010018A (es) Metodo para producir una composicion inmunogenica.
CL2018001704A1 (es) Productos lácteos saborizados
MX2019010266A (es) Proceso para la preparacion de yoduro de 3,7-bis(dimetilamino)feno tiazin-5-ilio.